Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK.

Subesinghe S, Rutherford AI, Ibrahim F, Harris H, Galloway J.

BMC Musculoskelet Disord. 2016 Aug 4;17:322. doi: 10.1186/s12891-016-1187-4.

2.

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis.

Elalouf O, Elkayam O.

Ther Clin Risk Manag. 2015 Nov 19;11:1719-26. doi: 10.2147/TCRM.S55928. eCollection 2015. Review.

3.

Ultrasound Detection of Salmonella Septic Arthritis in a Rheumatoid Arthritis Patient on Anti-TNF Treatment.

Nandagudi AC, Kelly S.

J Investig Med High Impact Case Rep. 2014 Apr 17;2(2):2324709614532799. doi: 10.1177/2324709614532799. eCollection 2014 Apr-Jun.

4.

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.

Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H.

Ann Rheum Dis. 2016 Jun;75(6):1133-8. doi: 10.1136/annrheumdis-2015-207319. Epub 2015 Aug 28.

5.

Hardware Removal Due to Infection after Open Reduction and Internal Fixation: Trends and Predictors.

Rasouli MR, Viola J, Maltenfort MG, Shahi A, Parvizi J, Krieg JC.

Arch Bone Jt Surg. 2015 Jul;3(3):184-92.

6.

Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.

Nyboe Andersen N, Pasternak B, Friis-Møller N, Andersson M, Jess T.

BMJ. 2015 Jun 5;350:h2809. doi: 10.1136/bmj.h2809.

7.

Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis.

Tong Q, Cai Q, de Mooij T, Xu X, Dai S, Qu W, Zhao D.

PLoS One. 2015 Mar 12;10(3):e0119897. doi: 10.1371/journal.pone.0119897. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0127488.

8.

Lymphocutaneous Sporotrichosis during Treatment with Anti-TNF-Alpha Monotherapy.

Ursini F, Russo E, Leporini C, Calabria M, Bruno C, Tripolino C, Naty S, Grembiale RD.

Case Rep Rheumatol. 2015;2015:614504. doi: 10.1155/2015/614504. Epub 2015 Feb 10.

9.

Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool.

Karp CL, Wilson CB, Stuart LM.

Immunol Rev. 2015 Mar;264(1):363-81. doi: 10.1111/imr.12270. Review.

10.

Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study.

Singh JA, Inacio MC, Namba RS, Paxton EW.

Arthritis Care Res (Hoboken). 2015 May;67(5):718-24. doi: 10.1002/acr.22497.

11.

Listeria meningitis and resultant symptomatic hydrocephalus complicating infliximab treatment for ulcerative colitis.

Rana F, Shaikh MM, Bowles J.

JRSM Open. 2014 Feb 26;5(3):2054270414522223. doi: 10.1177/2054270414522223. eCollection 2014 Mar.

12.

TNF-α Antagonist and Infection in Rheumatoid Arthritis.

Simard JF, Mittleman MA, Shadick NA, Karlson EW.

Open J Rheumatol Autoimmune Dis. 2012 May;2(2):14-20.

13.

Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.

Yoshitaka T, Ishida S, Mukai T, Kittaka M, Reichenberger EJ, Ueki Y.

J Bone Miner Res. 2014;29(5):1170-82. doi: 10.1002/jbmr.2125.

14.

Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.

Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, D'Amelio R.

J Transl Med. 2014 Mar 22;12:77. doi: 10.1186/1479-5876-12-77.

15.

The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection.

Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, Bocchino ML, Sanduzzi A, Scarpa R.

Clin Rheumatol. 2014 Apr;33(4):543-7. doi: 10.1007/s10067-014-2536-z. Epub 2014 Feb 21.

16.

Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy.

Yoo IK, Choung RS, Hyun JJ, Kim SY, Jung SW, Koo JS, Lee SW, Choi JH, Kim H, Lee HS, Keum B, Kim ES, Jeen YT.

Yonsei Med J. 2014 Mar;55(2):442-8. doi: 10.3349/ymj.2014.55.2.442.

17.

"Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".

Wasson NJ, Varley CD, Schwab P, Fu R, Winthrop KL.

BMC Infect Dis. 2013 Nov 11;13:533. doi: 10.1186/1471-2334-13-533.

18.

Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium.

Schiwon M, Weisheit C, Franken L, Gutweiler S, Dixit A, Meyer-Schwesinger C, Pohl JM, Maurice NJ, Thiebes S, Lorenz K, Quast T, Fuhrmann M, Baumgarten G, Lohse MJ, Opdenakker G, Bernhagen J, Bucala R, Panzer U, Kolanus W, Gröne HJ, Garbi N, Kastenmüller W, Knolle PA, Kurts C, Engel DR.

Cell. 2014 Jan 30;156(3):456-68. doi: 10.1016/j.cell.2014.01.006.

19.

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester GR, Matucci-Cerinic M, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, Kupper H.

Arthritis Res Ther. 2014 Jan 27;16(1):R24. doi: 10.1186/ar4452.

20.

A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment.

Kim J, Ryu H, Yoo DH, Park SH, Song GG, Park W, Cho CS, Song YW.

J Korean Med Sci. 2013 Dec;28(12):1716-22. doi: 10.3346/jkms.2013.28.12.1716. Epub 2013 Nov 26.

Items per page

Supplemental Content

Write to the Help Desk